New insights into the most pressing pharmacy topics

Prime’s clinical researchers presented four award-winning research studies at AMCP Nexus. Explore their findings, and learn about potential health and cost impacts.

Study 1: Cumulative Incidence and Incremental Claims Cost of Coronary Heart Disease Events in a Commercially Insured Cohort Stratified by Risk
Presented by: Kevin Bowen, principal health outcomes researcher
Recognition: AMCP Gold Award

When members who could benefit from cholesterol-lowering drug therapy aren’t being treated optimally, they’re at greater risk for coronary heart disease (CHD) events — and plan sponsors are on the hook for higher overall health care costs. To learn just how valuable CHD event prevention is, Prime studied the incidence of CHD events* and the associated incremental costs. Read more.

For more information, view the research poster and the press release.

Study 2: Statin Therapy, Intensity, Adherence and Number of Distinct Statins Tried Among Commercially Insured Adults with Atherosclerotic Cardiovascular Disease Continuously Enrolled Before and After 2013 ACC/AHA Cholesterol Guideline
Presented by: Kevin Bowen, principal health outcomes researcher
To determine appropriate PCSK9 inhibitor coverage, Prime analyzed its claims data and found current statin treatments were not being used or adhered to as guidelines recommend. Prime’s analysis validates that there is significant opportunity to optimize statin use, even for members who may be eligible for PCSK9s. Read more.

For more information, view the research poster and the press release.

Study 3: Medication Therapy Management (MTM) Comprehensive Medication Review (CMR) Impact Assessment
Presented by: Cathy Starner, principal health outcomes researcher
Recognition: AMCP Bronze Award

The Centers for Medicare and Medicaid Services requires prescription drug plan (PDP) sponsors to provide MTM programs. To learn how MTM programs impact adherence — and eventually Star ratings — our team of researchers compared adherence between qualified members who engaged in MTM vs. those who did not within the three drug adherence Star ratings categories. Read more.

For more information, view the research poster and the press release.

Study 4: Palbociclib (Ibrance®) Utilization and Costs among 18 Million Insured Americans: Managed Care Pharmacy Opportunities
Presented by Jennifer Baird, 2014 summer pharmacy intern under the direction of Pat Gleason, director of health outcomes
Recognition: AMCP Gold Award
At a cost of $476 per capsule, Ibrance has the potential to increase pharmacy costs for all stakeholders — not just people facing the certain type of breast cancer it treats. To learn what impact Ibrance could have on pharmacy benefit costs, our research team studied claims data from 18.6 million commercial and Medicare members.  Read more.

For more information, view the research poster and the press release.

blog comments powered by Disqus